United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 14,108 shares of United Therapeutics stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $113.51, for a total transaction of $1,601,399.08. Following the completion of the transaction, the chief executive officer now directly owns 7,194 shares of the company’s stock, valued at $816,590.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
UTHR opened at $114.86 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.32 and a quick ratio of 4.05. United Therapeutics Co. has a twelve month low of $100.06 and a twelve month high of $143.73. The company has a market cap of $4.95 billion, a PE ratio of 10.55, a P/E/G ratio of 42.74 and a beta of 1.12.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The company had revenue of $412.70 million for the quarter, compared to analysts’ expectations of $378.22 million. During the same period in the previous year, the firm earned $4.69 earnings per share. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Co. will post 14.28 EPS for the current fiscal year.
UTHR has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $118.00 to $126.00 and gave the stock a “neutral” rating in a report on Friday, November 2nd. ValuEngine cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Cowen set a $106.00 target price on shares of United Therapeutics and gave the stock a “hold” rating in a report on Thursday, November 15th. Oppenheimer set a $160.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 20th. Finally, Standpoint Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $134.00.
WARNING: This piece of content was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/01/12/martine-a-rothblatt-sells-14108-shares-of-united-therapeutics-co-uthr-stock.html.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.